CRSP Q1 Preview: Hype or Hope?

What happened

CRISPR Therapeutics reports Q1 earnings amid rising Casgevy uptake and positive Earnings ESP, but the DeepValue report warns that the company's collaboration expense structure and ongoing net losses contradict the narrative of near-term profitability. While Casgevy infusions reached 64 in 2025 and the patient funnel is expanding, the company expects Casgevy-related expenses to exceed its revenue share for the foreseeable future. The Q4 2025 net loss widened to $130.6M, and the $557.2M remaining ATM capacity poses dilution risk. The article's optimism about a beat may be short-lived if the underlying cost deferral mechanics and operational bottlenecks persist. Investors should focus on infusion cadence and ATM usage rather than a single earnings beat.

Implication

Until Casgevy conversion rate improves and collaboration expenses stabilize, CRSP remains a wait-and-see. Monitor for infusion acceleration above 60 per quarter and limited ATM draw.

Thesis delta

The article frames a potential Q1 beat as positive, but the DeepValue report's bearish fundamentals suggest any beat is unlikely to change the structural loss trend. Shift from 'earnings catalyst' to 'operational proof' needed.